Low PTEN levels and PIK3CA mutations predict resistance to neoadjuvant lapatinib and trastuzumab without chemotherapy in patients with HER2 over-expressing breast cancer.

Mothaffar F RimawiCarmine De AngelisAlejandro ContrerasFresia ParejaFelipe C GeyerKathleen A BurkeSabrina HerreraTao WangIngrid A MayerAndres ForeroRita NandaMatthew P GoetzJenny C ChangIan E KropAntonio C WolffAnne C PavlickSuzanne A W FuquaCarolina GutierrezSusan G HilsenbeckMarilyn M LiBritta WeigeltJorge S Reis-FilhoC Kent OsborneRachel Schiff

Published in: Breast cancer research and treatment (2017)

PI3K pathway activation is associated with resistance to lapatinib and trastuzumab in breast cancers, without chemotherapy. Further studies are warranted to investigate how to use these biomarkers to identify upfront patients who may respond to anti-HER2 alone, without chemotherapy.

Keyphrases

locally advanced
metastatic breast cancer
rectal cancer
epidermal growth factor receptor
radiation therapy
cell proliferation
chemotherapy induced
young adults
tyrosine kinase